^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Rectal Cancer |
| Drug: | Cyramza (ramucirumab) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Rectal cancer: UNRESECTABLE METACHRONOUS METASTASES...Previous adjuvant FOLFOX/CAPEOX within past 12 months...(FOLFIRI or irinotecan) ± (bevacizumab [preferred] or ziv-aflibercept or ramucirumab)
Secondary therapy:
FOLFIRI; irinotecan
